Translate Bio (NASDAQ:TBIO) Trading 5.2% Higher

Translate Bio Inc (NASDAQ:TBIO) traded up 5.2% on Monday . The stock traded as high as $8.89 and last traded at $8.77, 104,995 shares changed hands during mid-day trading. A decline of 56% from the average session volume of 236,065 shares. The stock had previously closed at $8.34.

Several equities analysts recently weighed in on the company. Zacks Investment Research raised Translate Bio from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. ValuEngine raised Translate Bio from a “sell” rating to a “hold” rating in a research note on Sunday, October 13th. Citigroup set a $17.00 price objective on Translate Bio and gave the company a “buy” rating in a research note on Tuesday, September 10th. Jefferies Financial Group assumed coverage on Translate Bio in a research note on Monday, July 22nd. They issued a “buy” rating and a $20.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Translate Bio in a research note on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $21.60.

The stock has a market capitalization of $447.36 million, a PE ratio of -2.47 and a beta of 0.92. The firm has a 50 day moving average of $9.62 and a two-hundred day moving average of $9.85. The company has a current ratio of 7.67, a quick ratio of 7.67 and a debt-to-equity ratio of 1.15.

Translate Bio (NASDAQ:TBIO) last announced its earnings results on Wednesday, July 31st. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). The company had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.73 million. Translate Bio had a negative net margin of 2,696.98% and a negative return on equity of 84.22%. Equities research analysts forecast that Translate Bio Inc will post -1.96 EPS for the current year.

A number of large investors have recently made changes to their positions in the business. Baupost Group LLC MA grew its holdings in Translate Bio by 36.2% during the 2nd quarter. Baupost Group LLC MA now owns 8,844,239 shares of the company’s stock valued at $109,372,000 after buying an additional 2,352,941 shares during the last quarter. BlackRock Inc. grew its holdings in Translate Bio by 28.0% during the 2nd quarter. BlackRock Inc. now owns 2,515,392 shares of the company’s stock valued at $31,769,000 after buying an additional 549,817 shares during the last quarter. Vanguard Group Inc. grew its holdings in Translate Bio by 80.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,524,907 shares of the company’s stock valued at $19,259,000 after buying an additional 680,330 shares during the last quarter. Artal Group S.A. grew its holdings in Translate Bio by 25.0% during the 2nd quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock valued at $9,473,000 after buying an additional 150,000 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Translate Bio by 7.5% during the 2nd quarter. Northern Trust Corp now owns 310,246 shares of the company’s stock valued at $3,919,000 after buying an additional 21,593 shares during the last quarter. Hedge funds and other institutional investors own 72.68% of the company’s stock.

About Translate Bio (NASDAQ:TBIO)

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

See Also: What is Liquidity?

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.